CareBright

CareBright.ie

CareBright is a long established Irish home care provider. Our focus is caring for and supporting people to live independently in their own homes. We have been providing services to the community since 1998 .We are a service provider for the HSE, in the form of Home Care Grants, Home Help Services, Chiropody, and Subsidised Hours in the home, while also providing care for clients in a private capacity.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Research

TETRASCIENCE R&D DATA CLOUD SELECTED BY LEADING CLINICAL-STAGE BIOTECHNOLOGY COMPANY

TetraScience | September 03, 2021

news image

TetraScience, the R&D Data Cloud company, announced today that Zymeworks Inc. has selected the Tetra Data Platform (TDP) to standardize and automate scientific data flow. As a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics, Zymeworks' R&D engine generates and analyzes large amounts of scientific data in its quest to revolutionize drug design. "In order to take advantage of innovative data sc...

Read More

MedTech

SEQUENCE BIO ANNOUNCES DISCOVERY COLLABORATION AGREEMENT WITH LEO PHARMA

Sequence Bio | April 08, 2022

news image

Sequence Bio, a Newfoundland and Labrador-based discovery biology company, announced today that it has entered into a collaboration agreement with Danish dermatology specialists LEO Pharma, for use of Sequence Bio's proprietary discovery platform to identify novel dermatologic drug targets. Under the terms of the three year agreement, Sequence Bio will perform multi-omic analyses of samples from powered discovery cohorts across multiple dermatologic indications. LEO Pharma will leverage insi...

Read More

Cell and Gene Therapy

TIZIANA LIFE SCIENCES ANNOUNCES GRANT RECEIVED BY THE BRIGHAM AND WOMEN’S HOSPITAL TO EXPLORE THE USE OF INTRANASAL ANTI-CD3 MAB

Tiziana Life Sciences Ltd. | September 16, 2022

news image

Tiziana Life Sciences Ltd. a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announces that a Lawrence & Isabel Barnett Drug Development Program Grant will be awarded to the Ann Romney Center for Neurologic Diseases at the Brigham and Women’s Hospital by the ALS Association for the study of an intranasal anti-CD3 monoclonal antibody in an animal model of Amyotrophic Lateral Sclerosis (ALS). Howard L. Weine...

Read More

Medical

NORDIC BIOSCIENCE AND ROCHE DIAGNOSTICS STRENGTHEN COLLABORATION FOR DEVELOPMENT OF BIOMARKERS FOR CHRONIC DISEASES

Nordic Bioscience | June 17, 2022

news image

Nordic Bioscience, a growing biomarker company, today announced the strengthening of its ongoing collaboration with Roche Diagnostics for the development of proprietary biomarkers involved in tissue breakdown and build-up. Nordic Bioscience is a world leader in Extra Cellular Matrix (ECM) biomarker development that can provide fast and objective decision-making for compound selection and development in clinical trials as well as provide value for patients in a diagnostic setting.<...

Read More
news image

Research

TETRASCIENCE R&D DATA CLOUD SELECTED BY LEADING CLINICAL-STAGE BIOTECHNOLOGY COMPANY

TetraScience | September 03, 2021

TetraScience, the R&D Data Cloud company, announced today that Zymeworks Inc. has selected the Tetra Data Platform (TDP) to standardize and automate scientific data flow. As a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics, Zymeworks' R&D engine generates and analyzes large amounts of scientific data in its quest to revolutionize drug design. "In order to take advantage of innovative data sc...

Read More
news image

MedTech

SEQUENCE BIO ANNOUNCES DISCOVERY COLLABORATION AGREEMENT WITH LEO PHARMA

Sequence Bio | April 08, 2022

Sequence Bio, a Newfoundland and Labrador-based discovery biology company, announced today that it has entered into a collaboration agreement with Danish dermatology specialists LEO Pharma, for use of Sequence Bio's proprietary discovery platform to identify novel dermatologic drug targets. Under the terms of the three year agreement, Sequence Bio will perform multi-omic analyses of samples from powered discovery cohorts across multiple dermatologic indications. LEO Pharma will leverage insi...

Read More
news image

Cell and Gene Therapy

TIZIANA LIFE SCIENCES ANNOUNCES GRANT RECEIVED BY THE BRIGHAM AND WOMEN’S HOSPITAL TO EXPLORE THE USE OF INTRANASAL ANTI-CD3 MAB

Tiziana Life Sciences Ltd. | September 16, 2022

Tiziana Life Sciences Ltd. a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announces that a Lawrence & Isabel Barnett Drug Development Program Grant will be awarded to the Ann Romney Center for Neurologic Diseases at the Brigham and Women’s Hospital by the ALS Association for the study of an intranasal anti-CD3 monoclonal antibody in an animal model of Amyotrophic Lateral Sclerosis (ALS). Howard L. Weine...

Read More
news image

Medical

NORDIC BIOSCIENCE AND ROCHE DIAGNOSTICS STRENGTHEN COLLABORATION FOR DEVELOPMENT OF BIOMARKERS FOR CHRONIC DISEASES

Nordic Bioscience | June 17, 2022

Nordic Bioscience, a growing biomarker company, today announced the strengthening of its ongoing collaboration with Roche Diagnostics for the development of proprietary biomarkers involved in tissue breakdown and build-up. Nordic Bioscience is a world leader in Extra Cellular Matrix (ECM) biomarker development that can provide fast and objective decision-making for compound selection and development in clinical trials as well as provide value for patients in a diagnostic setting.<...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us